Unknown

Dataset Information

0

Low-dose vemurafenib monotherapy in BRAFV600E -mutated Erdheim-Chester disease.

ABSTRACT:

SUBMITTER: Ruan GJ 

PROVIDER: S-EPMC8023000 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim-Chester disease patients following BRAF inhibitor monotherapy.
| S-EPMC7212923 | biostudies-literature
Unknown Successful re-treatment of a relapsed V600E mutated HCL patient with low-dose vemurafenib.
| S-EPMC4341463 | biostudies-literature
Unknown Vemurafenib enhances MHC induction in BRAF<sup>V600E</sup> homozygous melanoma cells.
| S-EPMC3583938 | biostudies-literature
Unknown Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAF<sup>V600E</sup> Conformation.
| S-EPMC5108658 | biostudies-literature
Unknown Erdheim-Chester disease presenting as acute ischaemic cardiomyopathy and aortitis in a <i>BRAF</i> V600E-negative patient.
| S-EPMC8355474 | biostudies-literature
Unknown Orbital and chorioretinal manifestations of Erdheim-Chester disease treated with vemurafenib.
| S-EPMC6076364 | biostudies-literature
Unknown Erdheim-Chester disease associated with a novel, complex BRAF p.Thr599_Val600delinsArgGlu mutation.
| S-EPMC5534755 | biostudies-literature
Unknown Acquired Secondary RAS Mutation in BRAF<sup>V600E</sup>-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors.
| S-EPMC7869871 | biostudies-literature
Unknown Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
| S-EPMC5844839 | biostudies-literature
Unknown Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
| S-EPMC3549296 | biostudies-literature